Yonsei Med J.  2005 Dec;46(6):788-793.

The Efficacy of the Prophylactic Use of Octreotide after a Pancreaticoduodenectomy

• Moon HJ
• Heo JS
• Choi SH
• Joh JW
• Choi DW
• Kim YI

Abstract

This study was performed to analyze the efficacy of the prophylactic use of octreotide (Novartis, Stein, Switzerland) for pancreatic fistula following a pancreaticoduodenectomy. The medical records of 190 patients who underwent a pancreaticoduodenectomy at the Samsung Medical Center in Seoul, Korea between January 2000 and December 2002 were reviewed. Patients were divided into either the octreotide (n = 81) or control group (n = 109). The octreotide group received subcutaneous injections of 100 microgramg of octreotide every 12 hours for more than five days after surgery. The control group was not treated with octreotide. The criterion of pancreatic fistula was the drainage of the amylase rich fluid, over 500 U/mL in the three days after surgery. The morbidity and mortality rates were 32.1% and 1.2% in the octreotide group and 31.2% and 0% in the control group, respectively. Pancreatic fistula was the second most common complication (8.4%). In the univariate analysis, octreotide was ineffective in reducing pancreatic fistula (p = 0.26). However, in the multivariate regression analysis, combined gastrectomy (p = 0.018), cellular origin of the disease (p = 0.049), and use of octreotide (p = 0.044) were the risk factors that increased the frequency of pancreatic fistula. Therefore, the routine use of octreotide after a pancreaticoduodenectomy should be avoided until a worldwide consensus is established.

Keyword

Pancreatic fistula; pancreaticoduodenectomy; octreotide

MeSH Terms

Postoperative Complications/*prevention & control
Pancreaticoduodenectomy/*adverse effects
Pancreatic Fistula/*prevention & control
Octreotide/*therapeutic use
Middle Aged
Male
Humans
Female

Reference

1. Trede M, Schwall G. The complications of pancreatectomy. Ann Surg. 1988. 207:39–47.

2. Yeo CJ. Management of complications following pancreaticoduodenectomy. Surg Clin North Am. 1995. 75:913–924.

3. Miedema BW, Sarr MG, van Heerden JA, Nagorney DM, McIlrath DC, Ilstrup D. Complications following pancreaticoduodenectomy. Current management. Arch Surg. 1992. 127:945–949. discussion 949-50.

4. Brodsky JT, Turnbull AD. Arterial hemorrhage after pancreatoduodenectomy. The 'sentinel bleed'. Arch Surg. 1991. 126:1037–1040.

5. Rumstadt B, Schwab M, Korth P, Samman M, Trede M. Hemorrhage after pancreatoduodenectomy. Ann Surg. 1998. 227:236–241.

6. Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak ML, Talamini MA, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg. 1995. 222:580–588. discussion 588-92.

7. Chou FF, Sheen-Chen SM, Chen YS, Chen MC, Chen CL. Postoperative morbidity and mortality of pancreaticoduodenectomy for periampullary cancer. Eur J Surg. 1996. 162:477–481.

8. Tran K, Van Eijck C, Di Carlo V, Hop WC, Zerbi A, Balzano G, et al. Occlusion of the pancreatic duct versus pancreaticojejunostomy: a prospective randomized trial. Ann Surg. 2002. 236:422–428.

9. Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg. 1995. 221:635–648.

10. Buchler M, Friess H, Klempa I, Hermanek P, Sulkowski U, Becker H, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg. 1992. 163:125–131.

11. Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ, et al. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg. 1995. 82:1270–1273.

12. Pederzoli P, Bassi C, Falconi M, Camboni MG. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg. 1994. 81:265–269.

13. Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E, Ribotta G, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery. 1995. 117:26–31.

14. Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997. 226:632–641.

15. Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg. 2000. 232:419–429.

16. Rosenberg L, MacNeil P, Turcotte L. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. J Gastrointest Surg. 1999. 3:225–232.

17. Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC, Brennan MF. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg. 2003. 196:954–964.

18. Li-Ling J, Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg. 2001. 88:190–199.

19. Kohler E, Beglinger C, Dettwiler S, Whitehouse I, Gyr K. Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas. 1986. 1:154–159.

20. Berberat PO, Friess H, Uhl W, Buchler MW. The role of octreotide in the prevention of complications following pancreatic resection. Digestion. 1999. 60:Suppl 2. 15–22.

21. Bottger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg. 1999. 23:164–172.

22. Berberat PO, Friess H, Kleeff J, Uhl W, Buchler MW. Prevention and treatment of complications in pancreatic cancer surgery. Dig Surg. 1999. 16:327–336.

23. Shyr YM, Su CH, Wu CW, Lui WY. Does drainage fluid amylase reflect pancreatic leakage after pancreaticoduodenectomy? World J Surg. 2003. 27:606–610.

24. Hashimoto N, Ohyanagi H. Pancreatic juice output and amylase level in the drainage fluid after pancreatoduodenectomy in relation to leakage. Hepatogastroenterology. 2002. 49:553–555.

25. Fujino Y, Suzuki Y, Ajiki T, Tanioka Y, Ku Y, Kuroda Y. Risk factors influencing pancreatic leakage and the mortality after pancreaticoduodenectomy in a medium-volume hospital. Hepatogastroenterology. 2002. 49:1124–1129.

26. Howard JM. Pancreatojejunostomy: leakage is a preventable complication of the Whipple resection. J Am Coll Surg. 1997. 184:454–457.

27. Hamanaka Y, Nishihara K, Hamasaki T, Kawabata A, Yamamoto S, Tsurumi M, et al. Pancreatic juice output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Surgery. 1996. 119:281–287.